Melinta Therapeutics Inc – Strategy, SWOT and Corporate Finance Report
- Pages: 51
- Published: June 2019
- Report Code: MLPH23928FSA
Melinta Therapeutics Inc – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company.
Melinta Therapeutics Inc (Melinta) is a biopharmaceutical company that focuses on the development of novel anti-infectives for the treatment of the various bacterial infections. Its marketed portfolio encompasses antibiotics for the treatment of serious bacterial infections including acute bacterial skin and skin structure infections (ABSSSI), complicated urinary tract infections (cUTI), and for the prevention and treatment of other serious infections that are caused by susceptible bacteria. The company is also evaluating delafloxacin in Phase 3 clinical trials for the treatment of serious community-acquired bacterial pneumonia (CABP) and and radezolid in Phase 2 clinical trials for dermatological diseases. Melinta's products and pipeline candidates are built on ribosome platform licensed from Yale University. The company distributes its products through partnership with Menarini Group; and Eurofarma Laboratorios. Melinta is headquartered at New Haven, Connecticut, the US.
Scope
Detailed information on Melinta Therapeutics Inc required for business and competitor intelligence needs
A study of the major internal and external factors affecting Melinta Therapeutics Inc in the form of a SWOT analysis
An in-depth view of the business model of Melinta Therapeutics Inc including a breakdown and examination of key business segments
News about Melinta Therapeutics Inc, such as business expansion, restructuring, and contract wins
Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
Gain understanding of Melinta Therapeutics Inc and the factors that influence its strategies.Track strategic initiatives of the company and latest corporate news and actions.
Assess Melinta Therapeutics Inc as a prospective partner, vendor or supplier.
Support sales activities by understanding your customers' businesses better.
Stay up to date on Melinta Therapeutics Incs business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
Merck & Co Inc
Zogenix Inc
Theravance Biopharma Inc
Monogram Biosciences Inc
Tetraphase Pharmaceuticals Inc
Sarepta Therapeutics Inc
Aduro BioTech Inc
GeoVax Labs Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.